Navigation Links
Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/4/2009

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the upcoming 11th Annual BIO CEO & Investor Conference at 11:30 a.m. Eastern Time on February 10, 2009 at the Waldorf-Astoria Hotel in New York City, NY.

The live webcast of this presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DALLAS , September 29, 2014 /PRNewswire/ ... market research report "Epigenetics Market by Product (Modifying ... Consumables, Kit, Bisulphite Conversion Kit, Reagents), by ... User - Global Forecast to 2019", published ... the major drivers, restraints, opportunities, current market ...
(Date:9/29/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, is ... to Chairman of the Board of Directors of ... continue to serve as a Director on the Board ... "We are very pleased to have ...
(Date:9/29/2014)... , Sept. 29, 2014  Perrigo Company plc ... that it has transferred a portfolio of preclinical ... 2013 acquisition of Elan Corporation plc, to drug ... of the agreement, Perrigo will receive an upfront ... and royalties on any future sales derived from ...
(Date:9/28/2014)... Boston, Mass. (PRWEB) September 29, 2014 ... delivers integrated cold chain management solutions for highly ... Brian Brazill, will present the company’s Advantage Transport ... Chain GDP & Temperature Management Logistics Global Forum ... will explain and demonstrate the company’s lab software ...
Breaking Biology Technology:Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... PARSIPPANY, N.J., Sept. 1, 2011 New data, published ... the long-term safety and tolerability of FIRMAGON ® ... cancer when used over three years.(1) The new study ... III study (CS21) in which FIRMAGON ® was ...
... BRUSSELS, September 1, 2011 The current ... successful research into blood-related diseases must ensure the safety ... This was a key message of a ... by the European Parliament and attended by doctors, researchers, ...
... September 1, 2011 The medical imaging ... has secured an order for their magnetic resonance imaging ... The software will be used in clinical practice to ... The software, SyMRI Diagnostics, includes tools to automatically ...
Cached Biology Technology:New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 3New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 4New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 5New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 6Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:9/29/2014)... President Juan Manuel Santos has presented Dr. Cristin ... Society, with the prestigious Order of San Carlos. ... citizens, foreign civilians and military officers who have ... the field of international relations. , An international ... Samper was invited to the Colombian Residence in ...
(Date:9/29/2014)... deemed inaccessible or esoteric. Yet in the modern world, ... daily lives and a decisive role in the discovery ... scenes. , UC Santa Barbara,s Paul Atzberger, a professor ... of mechanical engineering, often works in areas where science ... in the Proceedings of the National Academy of ...
(Date:9/29/2014)... a real-time feedback system together with a human energy ... reduction of 37% in energy consumption when compared to ... equivalent to a reduction of 713.71 kg of CO ... another eight halls, exposed only to the real-time feedback ... 3.5% reduction in energy consumption. , Student,s energy-use behaviour ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... for the planet,s gravest health threats is hatched by ... new report sets out a 10-point plan for this ... flu. Ministers of health and agriculture will formulate ... the threat of avian flu and other emerging infectious ...
... Integrates with,Citrix Password Manager Single-Sign On Solution ... Oct. 22 Fujitsu Computer Products of,America, ... products including,hard disk drives, peripherals and biometric ... has been verified as Citrix,Ready(TM). The PalmSecure ...
... The leading cause of death in all cancer patients ... a form of treatment in which chemicals are used to ... biochemists that focuses on cancer cells reports that ingesting apigenin ... fruit improves cancer cells, response to chemotherapy. ...
Cached Biology News:Avian flu threat: New approach needed 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 3Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 4How eating fruit and vegetables can improve cancer patients' response to chemotherapy 2
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Biology Products: